RNatives

Executive Summary

RNatives is a Finnish biotechnology company founded in 2019 and headquartered in Helsinki. The company is pioneering precision RNA-based gene regulating therapies that target nuclear non-coding RNAs to achieve long-lasting epigenetic changes and fine-tune gene expression. Their approach aims to treat serious diseases by leveraging the regulatory potential of non-coding RNAs, a relatively underexplored area in drug development. Despite being at an early stage, RNatives has a clear scientific focus and operates in the rapidly advancing field of RNA therapeutics, which has gained significant traction following the success of mRNA vaccines and the growing understanding of RNA biology. The company has not yet disclosed funding rounds or clinical stage, indicating it may still be in preclinical or discovery phases. However, their location in Helsinki provides access to a strong Nordic biotech ecosystem.

Upcoming Catalysts (preview)

• Q2 2027Series A Financing Round40% success
• Q4 2026Preclinical Proof-of-Concept Data Release50% success
• 2027Academic or Industry Partnership Announcement30% success